Clinical Trial Update: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immune response of an HIV-1 gp120 vaccine adjuvanted with GLA-SE in healthy, HIV-exposed uninfected infants; the study has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• HIV-1 CH505 transmitted/founder gp120 vaccine with GLA-SE adjuvant (gp120-based HIV vaccine with GLA-SE adjuvant)

Snippet

Sponsor: HIV Vaccine Trials Network | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2025-08-06